The antimicrobial sanitary pad industry is undergoing a critical standard iteration. In August 2026, T/CIAA 008—2026 for antimicrobial sanitary pads, pantyliners and period pants was officially released, replacing the 2020 version. The most significant change is the introduction of the concept of "long-lasting antimicrobial efficacy," requiring products to maintain bacteriostatic function under simulated use conditions. This signals the end of an era where initial inhibition rates were the only selling point, making long-term efficacy the new competitive focus.
Three Signals from the Standard Upgrade
This revision is not a simple wording adjustment but a systematic restructuring of product definitions, performance requirements, and test methods. In terms of definition, the standard name expanded from "bacteriostatic sanitary pads" to "antimicrobial sanitary pads, pantyliners and period pants," explicitly covering the fast-growing period pants category. Additionally, the new definition of "long-lasting antimicrobial efficacy" uses bovine serum albumin to simulate skin contact, maintaining conditions at 36±1°C for no less than 8 hours to verify the product's actual inhibitory performance during and after use. This design directly addresses a common industry pain point: many products perform well in laboratory settings but degrade under real-world conditions involving sweat and body temperature.
On the requirements front, the new standard fully aligns with GB 15979-2024, adjusting test methods for antibacterial performance, stability, and toxicology, while adding long-lasting efficacy indicators. This means future certified products must not only meet inhibitory standards at the factory gate but also prove effectiveness after simulated use. For manufacturers, this raises technical barriers while offering new opportunities for differentiation.
Ripple Effects Across the Supply Chain
The immediate impact of the standard upgrade is felt in the raw material segment. To achieve long-lasting efficacy, traditional surface spraying or dipping processes may no longer suffice. R&D will focus on antimicrobial agent selection, controlled-release technologies, and fiber substrate modification. Nanomaterials and microencapsulation are likely to gain traction. For upstream chemical fiber and nonwoven suppliers, closer collaboration with hygiene product makers is essential to develop customized long-acting antimicrobial raw materials.
For downstream brands and procurement teams, the revised standard changes verification and selection logic. Previously, initial inhibition rate reports might have sufficed; now, long-lasting efficacy data must be checked. Testing costs and lead times will increase, but this also provides clearer validation for quality suppliers. Notably, the standard is managed by the Zhongguancun Huizhi Antimicrobial New Materials Industry Technology Innovation Alliance, with drafting units including Henan Shulai, Guangdong Institute of Microbiology, SGS-CSTC, and Jinda Nano Technology (Xiamen), covering production, testing, and research expertise.
Industry Trends and Market Implications
From a broader perspective, this revision reflects the industry's shift from "antimicrobial concept" to "antimicrobial effectiveness." As consumer health awareness grows, simply labeling a product as "antibacterial" is insufficient; quantifiable, verifiable long-term indicators will be the core of future competition. Moreover, the update of GB 15979-2024 as a mandatory national standard inevitably drives revisions in group standards, and T/CIAA 008—2026 is a product of this synergy. It is foreseeable that other antimicrobial product standards (e.g., wipes, underwear) may follow suit, creating a more rigorous evaluation system.
For foreign trade companies, this standard offers valuable reference. Although group standards are not mandatory, the test methods involved (e.g., bovine serum albumin simulation) align with international trends toward evaluating long-term antimicrobial performance. Early adaptation can help exporters meet increasingly strict antimicrobial requirements in markets like Europe and the US.